{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-244590","form_type":"8-K","ticker":"TYRA","cik":"0001863127","company_name":"Tyra Biosciences, Inc.","filed_at":"2024-10-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.155656+00:00","generated_at":"2026-05-30T09:49:00.537046+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Tyra Biosciences receives FDA clearance for Phase 2 trial of TYRA-300 in achondroplasia","bullets":["FDA cleared IND for TYRA-300 Phase 2 trial (BEACH301) in children with achondroplasia ages 3-10.","BEACH301 is multicenter, open-label, dose-escalation/dose-expansion with two cohorts (naïve and prior therapy), up to 10 per dose level.","Primary endpoints: safety/tolerability and annualized growth velocity; secondary: height z-score, proportionality, PK.","First patient dosing expected Q1 2025; also plans IND for TYRA-300 in NMIBC by year-end 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-244590","json":"https://secwatch.observer/filing/0001193125-24-244590.json","markdown":"https://secwatch.observer/filing/0001193125-24-244590.md","text":"https://secwatch.observer/filing/0001193125-24-244590.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1863127/000119312524244590/0001193125-24-244590-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1863127/000119312524244590/d895225d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T09:49:00.537046+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}